API | radotinib

radotinib Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib. ^Wikipedia

Chemistry

SMILES: Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
InChIKey: DUPWHXBITIZIKZ-UHFFFAOYSA-N
Mol. Mass: 530.51
ALogP: 5.75 Partition coefficient
ChEMBL Molecule:
radotinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Breakpoint cluster region protein (Homo sapiens) ^UniProt
- Tyrosine-protein kinase ABL1 (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide | 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide hydrochloride | iy5511 | iy5511hcl | radotinib

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Bone Marrow Diseases (Phase 3)

Hematologic Diseases (Phase 3)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Parkinson Disease (Phase 2)

Philadelphia Chromosome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue